The story of the erectile dysfunction drug presents a complex picture for investors. While the initial introduction generated substantial gains, the end of its exclusive rights opened the door to cheaper versions, https://sb-bookmarking.com/story21751977/viagra-and-big-pharma-a-risky-bet